Agentix is a clinical-stage biotechnology company developing therapeutic agents for the treatment of the following metabolic diseases:
Type 2 diabetes mellitus
Obesity
Non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic steatohepatitis (NASH)
We currently have a portfolio of novel peripherally-acting small molecule therapeutic agents.
Therapeutic Strategy
Modulation of the Endocannabinoid System (ECS)
• The ECS is key to the regulatory system governing metabolism.
• Blockade of peripheral CB1 receptors results in:
· Sustained weight loss · Control of glucose and lipid metabolism · Improved insulin control · Modulation of gastrointestinal function
Role of the Endocannabinoid System in Management of Patients with Type 2 Diabetes Mellitus and Cardiovascular Risk Factors; Stephen N. Davis, MD, FRCP & Jennifer M. Perkins, MD; AACE Endocrine Practice Volume 13, ISSUE 7, P790-804, November 01, 2007
Restrict Therapeutic Activity to the Periphery
By increasing the topological polar surface area (tPSA), our molecules do not significantly cross the Blood-Brain Barrier.
The results of this strategy is demonstrated in our pre-clinical models:
No significant accumulation in the brain
Accumulation observed in the thigh muscle, heart, kidney and liver
Most significant accumation, by regional distribution, was observed in the liver